Pricing Log in Create free account
Friday 6 November 2026 Export GDRX’s income statement to Excel — free account

GoodRx Holdings, Inc.

GDRX Healthcare Health Information Services

GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024.

Revenue
−1.31%
EPS
−25.0%
Free cash flow
+112.5%
Total debt
−0.69%

Quarter to June 2026, against a year earlier

3.50 0.01 +0.29%
Market cap
$1.2B
P/E
65.7×
Fwd P/E
46.0×
Dividend yield
—
F-score
6/9
Altman Z
0.44
Beneish M
−2.40
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 9.68
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — 2 — — —
Insider Ownership 74.08%

Capital & Financial Ratios $m

Size
Market Cap 1,190.00
Revenue ttm 785.23
Net income ttm 16.25
Free cash flow ttm 131.70
Net debt Q 190.48
Valuation
P/E 65.67 (above 35: high)
Forward P/E 46.00 (above 35: high)
Price / sales 1.52
Forward P/S Powerpack
Price / FCF 9.07
Price / book 1.84
Financial health
Current ratio Q 1.38
Debt / equity Q 0.75
Interest coverage Q 2.41
Growth
Revenue growth Q −1.31% (below 0%: shrinking)
Operating income growth Q −11.85% (below 0%: shrinking)
EPS, this year −13.33% (below 0%: weak)
EPS, next year A +15.79% (at or above 15%: strong)
Revenue, next year A +0.21%
EPS, past 5 yrs —
EPS, next 5 yrs A +5.83%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 3.0×; over the ten years it ranged from 1.1× in 2026 to 27.6× in 2021.
P/S against its own 10 years 15.21%
10-year low 10-year high
P/B against its own 10 years 14.94%
10-year low 10-year high
EV/Sales against its own 10 years 15.21%
10-year low 10-year high
EV/FCF against its own 10 years 5.79%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 672 448 262 296
Receivables 144 146 236 182
Inventory — — — —
Other — 23 98 1,076
873 659 643 1,599
2023 2024 2025 Q'26
Payables 36 14 19 9
ST’ Debt 9 5 5 5
Other — 16 130 1,040
123 124 246 1,158

Compound Annual Growth %

10y 5y 3y
Sales — 7.67% 1.30%
Cash Flow — 5.03% 4.58%
Earnings — 0.00% 0.00%
Book Value — (2.83%) (8.89%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.08 Actual 0.08

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.09 0.08 Miss by 0.01
Q4 FY25 0.09 0.09 Met by 0.00
Q1 FY26 0.07 0.07 Met by 0.00
Q2 FY26 0.08 0.08 Met by 0.00
Q3 FY26 0.08 — Reports 3 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.02 — — —
’25 0.03 0.04 0.00 0.02 0.09
’24 0.00 0.02 0.01 0.02 0.04
’23 (0.01) 0.14 (0.09) (0.06) (0.02)
’22 0.03 0.00 (0.10) 0.00 (0.08)
’21 0.00 0.07 (0.04) (0.10) (0.06)
’20 0.12 0.12 (0.21) (1.09) (1.07)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 194 200 — — —
’25 203 203 196 195 797
’24 198 201 195 199 792
’23 184 190 180 197 750
’22 203 192 187 184 767
’21 160 177 195 213 745
’20 133 123 140 154 551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 12 81 — — —
’25 9 50 76 33 168
’24 43 10 87 45 184
’23 32 30 60 16 138
’22 30 51 34 32 147
’21 45 35 49 50 179
’20 46 38 33 15 131
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (10) 66 — — —
’25 (12) 31 58 17 94
’24 22 (8) 71 28 114
’23 18 15 47 3 83
’22 18 37 20 17 92
’21 36 28 40 41 144
’20 42 33 15 5 96
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 99 157 250 388 551 745 767 750 792 797 785 +26.0% 799 836 895 +3.9%
Gross margin, % 89.62 92.26 97.58 96.39 94.63 93.73 91.51 91.08 93.91 92.77 90.83 +3.1 pt
EBT 15 40 52 83 (303) (10) (23) (56) 31 57 41 +15.8%
EBT margin, % 15.20 25.25 20.98 21.37 (55.10) (1.37) (3.03) (7.41) 3.97 7.10 5.27 (8.1) pt
Net income (8) 0 44 66 (294) (25) (33) (9) 16 30 16 n/m
Per share, $
Per share, $ Revenue 0.26 0.41 2.23 1.71 2.00 1.82 1.86 1.83 2.05 2.24 2.31 +27.1%
Earnings (0.02) 0.02 0.12 0.19 (1.07) (0.06) (0.08) (0.02) 0.04 0.09 0.05 n/m
Cash flow 0.00 0.00 0.40 0.37 0.48 0.44 0.36 0.34 0.48 0.47 0.59 n/m
Capex 0.00 0.00 (0.03) (0.03) (0.13) (0.08) (0.13) (0.14) (0.18) (0.21) (0.21) n/m
Free cash flow 0.00 0.00 0.37 0.34 0.35 0.35 0.22 0.20 0.29 0.26 0.39 n/m
Book value 0.02 (0.22) (3.80) (1.55) 2.59 2.03 1.97 1.86 1.88 1.73 1.91 +63.4%
Shares, m 385 385 112 227 275 410 413 410 386 356 346 (0.9%)
Valuation, ×
Valuation, × P/E 138.66 138.66 138.66 138.66 0.00 0.00 0.00 0.00 98.10 30.04 65.67 68.3
P/S 24.64 24.64 24.64 24.64 20.12 17.97 2.54 3.07 2.26 1.21 1.52 14.6
P/B 0.00 0.00 0.00 0.00 15.58 16.11 2.39 3.03 2.48 1.57 1.84 4.1
EV/Sales 25.93 25.93 25.93 25.93 19.57 17.60 2.41 3.05 2.32 1.50 1.76 15.0
EV/FCF 79.93 79.93 79.93 79.93 112.82 90.91 20.16 27.75 16.18 12.70 10.51 60.0
Cash, $m
Cash, $m Operating cash flow — — 45 83 131 179 147 138 184 168 202 +20.6%
Capex — — (3) (6) (36) (34) (55) (56) (70) (74) (70) +54.9%
Free cash flow — — 42 78 96 144 92 83 114 94 132 +12.3%
Balance, $m
Balance, $m Working capital — — 56 53 1,027 1,008 843 750 535 397 441 +32.1%
Net debt 22 118 688 645 (305) (278) (98) (16) 43 226 190 +29.6%
Shareholders’ equity 8 (86) (425) (351) 711 832 815 762 725 616 648 +62.0%
Returns, %
Returns, % ROA (2.67) 5.98 4.66 12.19 (31.62) (1.64) (2.04) (0.56) 1.10 2.18 0.89 +4.9 pt
ROIC 0.00 0.00 18.41 29.66 (42.37) 1.51 0.15 (2.26) 5.36 6.49 5.59 +6.5 pt
ROE 3.77 (4.29) (2.01) (3.80) 156.09 (3.27) (3.99) (1.12) 2.21 4.54 2.52 +0.8 pt
People
People Employees — — — 338 478 777 954 694 738 697 — +12.8%
Revenue/emp, $m 0.00 0.00 0.00 1.15 1.15 0.96 0.80 1.08 1.07 1.14 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

GoodRx Holdings, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SDGR Schrodinger, Inc. $2.2B — (loss-making) — (loss-making) +18.72% (above 0%: growing) n/m +21.64% (above 0%: growing) 59.32% (40.52%) Compare
CERT Certara, Inc. $1.9B — (loss-making) — (loss-making) −9.29% (below 0%: shrinking) +300.00% (above 0%: growing) −12.09% (below 0%: shrinking) 66.87% 2.45% Compare
OMCL Omnicell, Inc. $1.7B 39.0× 32.9× −0.89% (below 0%: shrinking) +100.50% (above 0%: growing) +42.62% (above 0%: growing) 44.77% 4.85% Compare
TDOC Teladoc Health, Inc. $1.7B — (loss-making) — (loss-making) −3.41% (below 0%: shrinking) n/m +11.76% (above 0%: growing) 68.56% (4.64%) Compare
GDRX GoodRx Holdings, Inc. $1.2B 65.7× 46.0× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79%
OMDA Omada Health, Inc. $1.2B 267× 156× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
HSTM HealthStream, Inc. $905.6M 42.0× 45.4× +8.94% (above 0%: growing) −8.90% (below 0%: shrinking) −4.80% (below 0%: shrinking) 63.98% 7.91% Compare
PHR Phreesia, Inc. $788.9M 74.4× 40.2× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
NRC National Research Corporation $563.6M 87.6× 61.1× +10.95% (above 0%: growing) +22.22% (above 0%: growing) −31.38% (below 0%: shrinking) 59.95% 23.20% Compare
Median of peers $1.4B 74.4× 45.4× +9.68% +100.50% +16.70% 65.31% 4.45%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together less than 1% of the votes
Entities affiliated with Silver Lake 51.70% of the votes
Entities affiliated with Francisco Partners 24.60% of the votes
Idea Men, LLC 17.70% of the votes
Trevor Bezdek less than 1% of the votes
Douglas Hirsch less than 1% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

GoodRx Holdings, Inc. (GDRX) Latest News

29 Oct

Impact 4 · · Business Wire

5 Oct

Impact 3 · · StockStory

1 Oct

Impact 4 · · Insider Monkey

12 Aug

Impact 4 · · The Motley Fool transcript

11 Aug

Impact 4 ·

10 Aug

Impact 4 ·

6 Aug

Impact 4 · · MarketBeat transcript
Impact 4 · · Moby transcript

5 Aug

Impact 4 ·
Impact 4 ·

21 Jul

Impact 3 ·

17 Jun

Impact 3 ·

7 Jun

Impact 3 · · Insider Monkey

5 Jun

Impact 3 · · StockStory

28 May

Impact 3 · · Simply Wall St.

27 May

Impact 3 · · Business Wire

18 May

Impact 3 · · Bloomberg

16 May

Impact 3 · · StockStory

15 May

Impact 3 · · Simply Wall St.

8 May

Impact 4 · · The Motley Fool transcript

7 May

Impact 4 · · MarketBeat
Impact 4 · · Moby

6 May

Impact 4 ·
Impact 4 · · StockStory
Impact 4 · · Business Wire

1 May

Impact 4 · · Business Wire

15 Apr

Impact 4 ·

14 Apr

Impact 4 · · Zacks

9 Apr

Impact 4 · · Business Wire

24 Mar

Impact 4 · · Simply Wall St.
stockrow.com/GDRX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com